Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 9, December, p. 1447–1455

doi: 10.17219/acem/65094

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The role of pancreatic polypeptide in pancreatic diseases

Mariola Śliwińska-Mossoń1,A,B,C,D,E, Grzegorz Marek2,C,D,E, Halina Milnerowicz1,A,E,F

1 Department of Biomedical and Environmental Analyses, Wroclaw Medical University, Poland

2 Second Department and Clinic of General and Oncological Surgery, Wroclaw Medical University, Poland

Abstract

The aim of this study was to review the diagnostic significance of pancreatic polypeptide (PP) in pancreatic diseases. PP may play a significant role in monitoring the development of the disease and the patient’s healing process, particularly after the removal of a portion of the pancreas. Determining PP in acute pancreatitis is quite controversial. At the 1st stage of severe pancreatic damage, there is excessive PP release followed by its fall. In patients with chronic pancreatitis, a significant decrease in PP secretion was found in the presence of a food stimulant. In this case, PP could be a good marker for determining the stage of pancreatitis. Pancreatic polypeptide also functions as a hepatic glucose regulator. PP increases hepatic insulin sensitivity, resulting in reduced hepatic glucose production. Therefore, impaired hepatic insulin sensitivity in chronic pancreatitis is abrogated after the PP administration. Endocrine pancreatic tumors initially grow without specific symptoms. In contrast, they are almost always correlated with elevated serum pancreatic polypeptide. Therefore, the level of PP may be a good diagnostic parameter confirming the presence of pancreatic cancer. Depending on the type of disease, the polypeptide concentration can be increased or decreased, evidencing the disease progress or regression.

Key words

pancreatic polypeptide, acute pancreatitis, chronic pancreatitis, diabetes

References (39)

  1. Hennig R, Kekis PB, Friess H, Adrian TE, Büchler MW. Pancreatic polypeptide in pancreatitis. Peptides. 2002;23:331–338.
  2. Śliwińska-Mossoń M, Milnerowicz H, Milnerowicz S, Nowak M, Rabczyński J. Immunohistochemical localization of somatostatin and pancreatic polypeptide in smokers with chronic pancreatitis. Acta Histochem. 2012;5:495–502.
  3. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J. 2010;57:359–372.
  4. Piao FL, Yuan K, Bai GY, Han JH, Park WH, Kim SH. Different regulation of atrial ANP release through neuropeptide Y2 and Y4 receptors. J Korean Med Sci. 2008;23:1027–1032.
  5. Śliwińska-Mossoń M, Borowiecka K, Milnerowicz H. Neuropeptides Y, YY, PP and their clinical significance. Postepy Hig Med Dosw. 2013;67:631–636.
  6. Lundell I, Blomqvist AG, Berglund MM, et al. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J Biol Chem. 1995;270:29123–29128.
  7. Kim W, Fiori JL, Shin YK, et al. Pancreatic polypeptide inhibits somatostatin secretion. FEBS Lett. 2014;588:3233–3239.
  8. Kojima S, Ueno N, Asakawa A, et al. A role for pancreatic polypeptide in feeding and body weight regulation. Peptides. 2007;28:459–463.
  9. Gingerich RL, Akpan JO, Leith KM, Gilbert WR. Patterns of immunoreactive pancreatic polypeptide in human plasma. Regul Pept. 1991;33:275–285.
  10. Hazelwood RL. The pancreatic polypeptide (PP-Fold) family: Gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med. 1993;202:44–63.
  11. Katsuura G, Asakawa A, Inui A. Roles of pancreatic polypeptide in regulation of food intake. Peptides. 2002;23:323–329.
  12. Ueno N, Inui A, Iwamoto M, et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology. 1999;117:1427–1432.
  13. Berntson GG, Zipf WB, O’Dorisio TM, Hoffman JA, Chance RE. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides. 1993;14:497–503.
  14. Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology. 2003;124:1325–1336.
  15. Shi YC, Lin Z, Lau J, et al. PYY3-36 and pancreatic polypeptide reduce food intake in an additive manner via distinct hypothalamic dependent pathways in mice. Obesity. 2013;12:669–678.
  16. Sainsbury A, Bergen HT, Boey D, et al. Y2Y4 receptor double knockout protects against obesity due to a high-fat diet or Y1 receptor deficiency in mice. Diabetes. 2006;55:19–26.
  17. Yulyaningsih E, Loh K, Lin S, et al. Pancreatic polypeptide controls energy homeostasis via Npy6r signaling in the suprachiasmatic nucleus in mice. Cell Metab. 2014;19:58–72.
  18. Batterham RL, le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88:3989–3992.
  19. Glaser B, Zoghlin G, Pienta K, Vinik AI. Pancreatic polypeptide response to secretin in obesity: Effects of glucose intolerance. Horm Metab Res. 1988;20:288–292.
  20. Taylor IL, Impicciatore M, Carter DC, Walsh JH. Effect of atropine and vagotomy on pancreatic polypeptide response to a meal in dogs. Am J Physiol. 1978;235:443–447.
  21. Linnestad P, Schrumpf E. Pancreatic polypeptide release stimulated by food, secretin and cholecystokinin in chronic pancreatitis. Scand J Gastroenterol. 1983;18:385–389.
  22. Dembińska-Kieć A, Naskalski JW. Laboratory Diagnosis of Clinical Biochemistry Elements. 3rd ed. Wrocław: Urban & Partner; 2010:744–747.
  23. Pappas TN, Yovos JG, Ellison EC, et al. Pancreatic polypeptide in acute pancreatitis and small-bowel infarction in dogs. Dig Dis Sci. 1981;26:1013–1018.
  24. Dominguez-Munoz JE, Pieramico O, Büchler M, Malfertheiner P. Exocrine pancreatic function in the early phase of human acute pancreatitis. Scand J Gastroenterol. 1995;30:186–191.
  25. Matsumoto M, Wakasugi H, Ibayashi H. Plasma human pancreatic polypeptide response in chronic pancreatitis. Gastroenterol Jpn. 1982;17:25–30.
  26. Śliwińska-Mossoń M, Milnerowicz H. Distribution of pancreatic polypeptide-secreting endocrine cells in nondiabetic and diabetic cases. Appl Immunohistochem Mol Morphol. 2016. [Epub ahead of print]
  27. Valenzuela JE, Taylor IL, Walsh JH. Pancreatic polypeptide response in patients with chronic pancreatitis. Dig Dis Sci. 1979;24:862–864.
  28. Larsen S, Hilsted J, Tronier B, Worning H. Pancreatic hormone secretion in chronic pancreatitis without residual β-cell function. Acta Endocrinol (Copenh). 1988;118:357–364.
  29. Bastidas JA, Couse NF, Yeo CJ, et al. The effect of pancreatic polypeptide infusion on glucose tolerance and insulin response in longitudinally studied pancreatitis-induced diabetes. Surgery. 1990;107:661–668.
  30. Harris AG. Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects. Gut. 1994;35(Suppl 3):1–4.
  31. Huml M, Kobr J, Siala K, et al. Gut peptide hormones and pediatric type 1 diabetes mellitus. Physiol Res. 2011;60:647–658.
  32. Floyd JC Jr, Fajans SS, Pek S, Chance RE. A newly recognized pancreatic polypeptide: Plasma levels in health and disease. Recent Prog Horm Res. 1976;33:519–570.
  33. Śliwińska-Mossoń M, Veselý M, Milnerowicz H. The clinical significance of somatostatin in pancreatic diseases. Ann Endocrinol (Paris). 2014;75:232–240.
  34. Brunicardi FC, Chaiken RL, Ryan AS. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996;81:3566–3572.
  35. Diem P, Redmon BR, Abid M, et al. Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest. 1990;86:2008–2013.
  36. Maeda H, Hanazaki H. Pancreatogenic diabetes after pancreatic resection. Pancreatology. 2011;11:268–276.
  37. Bordi C, Azzoni C, D’Adda T, Pizzi S. Pancreatic polypeptide-related tumors. Peptides. 2002;23:339–348.
  38. Bellows C, Hague S, Jaffe B. Pancreatic polypeptide islet cell tumor: Case report and review of the literature. J Gastrointest Surg. 1998;2:526–532.
  39. Mutch MG, Frisella MM, DeBenedetti MK, et al. Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. Surgery. 1997;122:1012–1020.